Breast cancer remains one of the most prevalent and life-threatening diseases worldwide, with early detection being crucial for effective treatment. However, current screening methods, such as mammograms, have limitations. They can be expensive, inaccessible in certain regions, and sometimes yield false positives or negatives, causing unnecessary stress or missed diagnoses. Moreover, mammograms involve radiation exposure, which raises additional concerns.
To address these challenges, The Blue Box Biomedical Solutions has developed an innovative, non-invasive, and affordable alternative: a device that detects breast cancer using a simple urine sample. This groundbreaking technology functions similarly to a pregnancy test, making it easy to use and widely accessible. The device, called The Blue Box, employs an electronic nose (eNose) with chemical sensors that analyze volatile biomarkers in urine, which are then interpreted by an AI algorithm to detect cancer with remarkable accuracy.
So far, two pilot studies involving 450 patients across seven Spanish hospitals have been conducted. If it successfully clears the final stages of testing and obtains regulatory approval, the device could be fully operational by 2026.
Winning the EmprendeXXI Award grants The Blue Box Biomedical Solutions a spot in an international acceleration program in Berlin, organized with ICEX, providing valuable connections with investors and industry leaders. If successfully certified, this innovation could transform breast cancer screening by offering a radiation-free, cost-effective, and accessible diagnostic tool for millions worldwide.
Article written by Alberto perez
05/03/205
Source:
Directivos y empresas